Relevant bibliographies by topics / Pediatric pharmacology / Journal articles
To see the other types of publications on this topic, follow the link: Pediatric pharmacology.

Journal articles on the topic 'Pediatric pharmacology'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 August 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pediatric pharmacology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Peiré García, Mª Asunción. "Pediatric pharmacology." ANALES RANM 136, no. 02 (September 25, 2019): 218–21. http://dx.doi.org/10.32440/ar.2019.136.02.rev17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kaguelidou, Florentia, Behrouz Kassai Koupai, and Genevieve Durrieu. "Pediatric pharmacology." Therapies 73, no. 2 (April 2018): 111–12. http://dx.doi.org/10.1016/j.therap.2018.02.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Poon, Cathy Y., and Rosalie Sagraves. "Pediatric pharmacology." Journal of Pediatric Health Care 7, no. 3 (May 1993): 127–33. http://dx.doi.org/10.1016/0891-5245(93)90093-w.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mukherjee, B. P. "Pediatric pharmacology." Indian Journal of Otolaryngology and Head and Neck Surgery 46, no. 4 (October 1994): 233. http://dx.doi.org/10.1007/bf03048593.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

KIMURA, TOSHIMI. "Clinical Pharmacology of Pediatric Patients: Pharmacology of Antibiotics in Pediatrics." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 35, no. 6 (2004): 280–84. http://dx.doi.org/10.3999/jscpt.35.6_280.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sepúlveda, Pablo O., Valeria Epulef, and Gustavo Campos. "Why do We Use the Concepts of Adult Anesthesia Pharmacology in Developing Brains? Will It Have an Impact on Outcomes? Challenges in Neuromonitoring and Pharmacology in Pediatric Anesthesia." Journal of Clinical Medicine 10, no. 10 (May 18, 2021): 2175. http://dx.doi.org/10.3390/jcm10102175.

Full text
Abstract:
Background: Pediatric sedation and anesthesia techniques have plenty of difficulties and challenges. Data on the pharmacologic, electroencephalographic, and neurologic response to anesthesia at different brain development times are only partially known. New data in neuroscience, pharmacology, and intraoperative neuromonitoring will impact changing concepts and clinical practice. In this article, we develop a conversation to guide the debate and search for a view more attuned to the updated knowledge in neurodevelopment, electroencephalography, and clinical pharmacology for the anesthesiologic practice in the pediatric population.
APA, Harvard, Vancouver, ISO, and other styles
7

Woo, Teri Moser. "Pediatric Pharmacology Update." Advances in Family Practice Nursing 3 (May 2021): 169–81. http://dx.doi.org/10.1016/j.yfpn.2021.02.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Park, Min Soo. "Pediatric Clinical Pharmacology." Journal of Korean Society for Clinical Pharmacology and Therapeutics 4, no. 2 (1996): 239. http://dx.doi.org/10.12793/jkscpt.1996.4.2.239.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zaritsky, Arno. "Pediatric resuscitation pharmacology." Annals of Emergency Medicine 22, no. 2 (February 1993): 445–55. http://dx.doi.org/10.1016/s0196-0644(05)80477-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pelayo, Rafael, and Kin Yuen. "Pediatric Sleep Pharmacology." Child and Adolescent Psychiatric Clinics of North America 21, no. 4 (October 2012): 861–83. http://dx.doi.org/10.1016/j.chc.2012.08.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Pelayo, Rafael, and Michael Dubik. "Pediatric Sleep Pharmacology." Seminars in Pediatric Neurology 15, no. 2 (June 2008): 79–90. http://dx.doi.org/10.1016/j.spen.2008.03.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

FURLANUT, M. "Pediatric clinical pharmacology." Pharmacological Research 26 (September 1992): 221. http://dx.doi.org/10.1016/1043-6618(92)91151-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

ECHIZEN, HIROTOSHI. "Clinical Pharmacology of Pediatric Patients: Basic Aspects of Pediatric Pharmacology." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 35, no. 6 (2004): 271–74. http://dx.doi.org/10.3999/jscpt.35.6_271.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Ito, Shinya, Hidefumi Nakamura, and Tohru Kobayashi. "Pediatric Pharmacology in Japan." Pediatric Drugs 14, no. 4 (August 2012): 247–49. http://dx.doi.org/10.2165/11633160-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

L., J. F. "PROGRESS IN PEDIATRIC PHARMACOLOGY." Pediatrics 88, no. 5 (November 1, 1991): 1062. http://dx.doi.org/10.1542/peds.88.5.1062.

Full text
Abstract:
The survey by the Pharmaceutical Manufacturers Association has identified 114 drugs and vaccines that are being developed specifically for pediatric use. . . • The 114 medicines involve 127 clinical testing research projects, since some are being tested for more than one use. An example is Prokine, a colony stimulating factor being tested by Hoechst-Roussel and Immunex for two kinds of blood disorders, for cancer, and for bone marrow transplantation. • 56 companies are involved in these research projects, a very broad base of companies that again, I think, reflects the strong research capabilities of the private sector. • Nearly two-thirds of the projects are in the final stages of development: 45 are in the Phase III human clinical tests and another 35 are at the Food and Drug Administration for review. • Fully a quarter of our research projects—32 to be exact—are for rare diseases and are designated as orphan drugs on the chart.
APA, Harvard, Vancouver, ISO, and other styles
16

Ushay, H. Michael, and Daniel A. Notterman. "PHARMACOLOGY OF PEDIATRIC RESUSCITATION." Pediatric Clinics of North America 44, no. 1 (February 1997): 207–33. http://dx.doi.org/10.1016/s0031-3955(05)70470-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Puntis, J. "Pediatric Pharmacology and Therapeutics." Archives of Disease in Childhood 70, no. 1 (January 1, 1994): 73–74. http://dx.doi.org/10.1136/adc.70.1.73-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

MacLeod, Stuart, Robert Peterson, Yi Wang, Zhiping Li, Yonghao Gui, and Jane Schaller. "Challenges in International Pediatric Pharmacology." Pediatric Drugs 9, no. 4 (2007): 215–18. http://dx.doi.org/10.2165/00148581-200709040-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Choonara, I. A. "Textbook on Pediatric Clinical Pharmacology." Archives of Disease in Childhood 61, no. 6 (June 1, 1986): 625–26. http://dx.doi.org/10.1136/adc.61.6.625-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Aranda, Jacob V. "Pediatric Pharmacology and Drug Therapy." Pediatric Clinics of North America 64, no. 6 (December 2017): i. http://dx.doi.org/10.1016/s0031-3955(17)30152-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

van den Anker, John N., Max J. Coppes, and Gideon Koren. "Neonatal and Pediatric Clinical Pharmacology." Pediatric Clinics of North America 59, no. 5 (October 2012): xv—xviii. http://dx.doi.org/10.1016/j.pcl.2012.07.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Troester, Matthew M., and Rafael Pelayo. "Pediatric Sleep Pharmacology: A Primer." Seminars in Pediatric Neurology 22, no. 2 (June 2015): 135–47. http://dx.doi.org/10.1016/j.spen.2015.03.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Groll, Andreas H., Emmanuel Roilides, and Thomas J. Walsh. "Pediatric pharmacology of antifungal agents." Current Fungal Infection Reports 2, no. 1 (March 2008): 49–56. http://dx.doi.org/10.1007/s12281-008-0008-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Levine, Stuart, Kay Holbrook, Barbara O'connor-Pepe, and Deidre Shinn. "Medication Safety in the Pediatric Emergency Department." Hospital Pharmacy 38, no. 5 (May 2003): 426–35. http://dx.doi.org/10.1177/001857870303800515.

Full text
Abstract:
This continuing feature will focus on recent advancements in the areas of pediatrics and neonatal pharmacology and on methods for reducing medication error risk in this patient population. Most pharmacological agents are designed with the adult in mind, and there is little literature-based data from which to derive dosing schedules and proper drug administration techniques for the pediatric and neonatal patient. Moreover, pharmacological response in this group is not well understood. We hope that this feature will help you provide pharmaceutical care to this high-risk population. Direct questions or comments to Stuart Levine, PharmD, at slevine@nemours.org .
APA, Harvard, Vancouver, ISO, and other styles
25

Knoppert, David, Sara Arenas-Lopez, and Rowena McArtney. "The Infancy of an International Paediatric Pharmacy Network." Journal of Pediatric Pharmacology and Therapeutics 13, no. 1 (January 1, 2008): 51–54. http://dx.doi.org/10.5863/1551-6776-13.1.51.

Full text
Abstract:
There are several pharmacy and clinical pharmacology organizations in which pediatrics is one of many special interest groups and a few whose focus is entirely pediatric drug therapy. Recently the foundation for the establishment of an International Network of Paediatric Pharmacists has been laid. This paper describes that network.
APA, Harvard, Vancouver, ISO, and other styles
26

Yaffe, Sumner J. "Pediatric Pharmacology: Its Time Has Come." Journal of Pediatric Pharmacology and Therapeutics 8, no. 1 (January 1, 2003): 10–12. http://dx.doi.org/10.5863/1551-6776-8.1.10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Koren, Gideon, Michael Rieder, and Stuart M. MacLeod. "The Global Alliance for Pediatric Pharmacology." Pediatric Drugs 11, no. 1 (2009): 4–5. http://dx.doi.org/10.2165/0148581-200911010-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Koren, Gideon. "Training Clinicians in Pediatric Pharmacology-Toxicology." Pediatric Drugs 11, no. 1 (2009): 60–62. http://dx.doi.org/10.2165/0148581-200911010-00020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Ramamurthi, R. J., and Elliot J. Krane. "Local anesthetic pharmacology in pediatric anesthesia." Techniques in Regional Anesthesia and Pain Management 11, no. 4 (October 2007): 229–34. http://dx.doi.org/10.1053/j.trap.2007.09.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Wilson, John T. "Clinical Pharmacology of Pediatric Antipyretic Drugs." Therapeutic Drug Monitoring 7, no. 1 (March 1985): 2–11. http://dx.doi.org/10.1097/00007691-198503000-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Nariharan, Selena, and Mary Patterson. "A review of pediatric resuscitation pharmacology." Clinical Pediatric Emergency Medicine 2, no. 2 (June 2001): 124–28. http://dx.doi.org/10.1016/s1522-8401(01)90015-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Bissenden, J. G. "Pediatric Pharmacology: Therapeutic Principles in Practice." Archives of Disease in Childhood 67, no. 10 (October 1, 1992): 1321. http://dx.doi.org/10.1136/adc.67.10.1321-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

McClain, Brenda C., and Benjamin Lee. "Applied pharmacology in pediatric pain management." Current Review of Pain 1, no. 4 (December 1997): 296–309. http://dx.doi.org/10.1007/bf02938299.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 44, no. 1 (1997): 545–74. http://dx.doi.org/10.1016/s0065-3101(24)00062-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 42, no. 1 (1995): 593–629. http://dx.doi.org/10.1016/s0065-3101(24)00126-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 40, no. 1 (1993): 405–39. http://dx.doi.org/10.1016/s0065-3101(24)00020-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 32, no. 1 (1985): 589–618. http://dx.doi.org/10.1016/s0065-3101(24)00232-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 34, no. 1 (1987): 411–43. http://dx.doi.org/10.1016/s0065-3101(24)00167-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 36, no. 1 (1989): 431–59. http://dx.doi.org/10.1016/s0065-3101(24)00147-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Berlin, Cheston M. "Advances in Pediatric Pharmacology and Toxicology." Advances in Pediatrics 38, no. 1 (1991): 389–413. http://dx.doi.org/10.1016/s0065-3101(24)00272-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Subramanian, Deejesh, Cintia V. Cruz, and Facundo Garcia-Bournissen. "Systematic Review of Early Phase Pediatric Clinical Pharmacology Trials." Journal of Pediatric Pharmacology and Therapeutics 27, no. 7 (September 1, 2022): 609–17. http://dx.doi.org/10.5863/1551-6776-27.7.609.

Full text
Abstract:
OBJECTIVE Children have generally been excluded from early-stage clinical trials owing to safety concerns based in social expectations and not data. However, the repositioning of adult therapeutics for pediatric use and the increase in the development of therapies for pediatric only conditions require the participation of children in phase 1–2 trials. Therefore, the aim of this article is to systematically review the history and current state of early phase pediatric clinical pharmacology trials in order to understand safety concerns, trends, and challenges in pediatric trials. METHODS This review analyzed the nature of early phase pediatric clinical trials conducted for nononcology conditions through a systematic search that was performed for pediatric non-oncologic phase 1 or phase 1–2 drug and vaccine studies in MEDLINE. RESULTS The data show that the number of early phase pediatric clinical trials is still small relative to adults but has been on the rise in the past decade with relatively few serious adverse effects observed. CONCLUSIONS The widespread concerns about children's safety when they participate in early phase clinical trials seem disproportionate, based on our findings. The data confirm that these studies can be conducted safely, and that their results can contribute significantly to pediatric pharmacotherapy.
APA, Harvard, Vancouver, ISO, and other styles
42

Gaudreault, Pierre. "Nonsteroidal Anti-Inflammatory Agents in the Treatment of Asthma in Children." Canadian Respiratory Journal 2, suppl a (1995): 24A—31A. http://dx.doi.org/10.1155/1995/956715.

Full text
Abstract:
The increasing scientific information clearly demonstrates the important role of inflammation in asthma. This evidence has led physicians to focus their treatment on the elimination of inflammation instead of working solely against bronchoconstriction. Steroids and nonsteroidal agents are currently used to prevent this inflammatory component. This paper focuses only on nonstcroidal anti-inflammatory agents such as sodium cromoglycate, nedocromil sodium and ketotifen and their use in pediatric asthma. The discussion on each medication addresses its mechanism of action, the evidence concerning its efficacy in pediatrics (ie, clinical pharmacology, acute bronchial challenge, late asthmatic response, bronchial hyperrcactivity, clinical efficacy) and the pediatric dose.
APA, Harvard, Vancouver, ISO, and other styles
43

Holland, Diane T., Robin DiFrancesco, Judith Stone, Fayez Hamzeh, James D. Connor, and Gene D. Morse. "Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories." Antimicrobial Agents and Chemotherapy 48, no. 3 (March 2004): 824–31. http://dx.doi.org/10.1128/aac.48.3.824-831.2004.

Full text
Abstract:
ABSTRACT Clinical trials designed to compare antiretroviral regimens, investigate therapeutic drug monitoring, or measure pharmacometrics often include protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, requiring the measurement of these antiretrovirals in plasma. Within the adult and pediatric AIDS Clinical Trials Group (ACTG), a network of Pharmacology Support Laboratories (PSLs) is a component of the group laboratory infrastructure and conducts these types of pharmacologic assays. The adult ACTG has developed a comprehensive quality assurance program for the conduct of clinical pharmacology protocols, one component of which is the antiretroviral proficiency testing (PT) program that has been implemented between the adult and pediatric pharmacology laboratories of the ACTG. PT testing samples were prepared and distributed in July 2001, February 2002, and July 2002. High, medium, and low concentrations of PIs (indinavir, saquinavir, amprenavir, lopinavir, ritonavir, and nelfinavir) and NNRTIs (nevirapine and efavirenz) were added to drug-free EDTA plasma and distributed, on dry ice, to eight ACTG PSLs. One testing laboratory used liquid chromatography-tandem mass spectrometry, and seven used high-performance liquid chromatography-UV analysis. A result was considered acceptable if it was within 20% deviation of the assigned concentration. For all concentrations of PIs evaluated, 96% of samples tested (430 of 448 measurements) met the acceptance criteria. For both NNRTIs, 100% of samples tested (140 of 140 measurements) met the acceptance criteria. In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
44

Garcia-Bournissen, Facundo, Jaime Altcheh, Norberto Giglio, Guido Mastrantonio, Carlos Omar Della Védova, and Gideon Koren. "Pediatric Clinical Pharmacology Studies in Chagas Disease." Pediatric Drugs 11, no. 1 (2009): 33–37. http://dx.doi.org/10.2165/0148581-200911010-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Koren, Gideon, Milan Kriska, Gerrard Pons, Neil Shear, Emilio Sanz, and Stuart Macleod. "The network of pediatric pharmacology training programs." Clinical Pharmacology and Therapeutics 54, no. 1 (July 1993): 1–6. http://dx.doi.org/10.1038/clpt.1993.99.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Paul, Ian M. "Advances in Pediatric Pharmacology, Therapeutics, and Toxicology." Advances in Pediatrics 52 (January 2005): 321–65. http://dx.doi.org/10.1016/j.yapd.2005.03.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Paul, Ian M. "Advances in Pediatric Pharmacology, Therapeutics, and Toxicology." Advances in Pediatrics 54, no. 1 (January 2007): 29–53. http://dx.doi.org/10.1016/j.yapd.2007.03.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Paul, Ian M. "Advances in Pediatric Pharmacology, Therapeutics, and Toxicology." Advances in Pediatrics 57, no. 1 (January 2010): 163–83. http://dx.doi.org/10.1016/j.yapd.2010.08.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Paul, Ian M. "Advances in Pediatric Pharmacology, Therapeutics, and Toxicology." Advances in Pediatrics 59, no. 1 (January 2012): 27–45. http://dx.doi.org/10.1016/j.yapd.2012.04.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Gonzalez, Daniel, Ian M. Paul, Daniel K. Benjamin, and Michael Cohen-Wolkowiez. "Advances in Pediatric Pharmacology, Therapeutics, and Toxicology." Advances in Pediatrics 61, no. 1 (August 2014): 7–31. http://dx.doi.org/10.1016/j.yapd.2014.03.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Pediatric pharmacology' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography